TLR7 and myeloid sarcoma: In summary, our work, including both studies on immune cells from healthy donors and on patients with MS, implicates that modulation of the innate immune response may be a relevant mechanism of action of interferon-β in patients with MS and suggests a role for the innate immune receptor TLR7 as an important target in this context.